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Background—The available prognostic models for overall survival (OS) in patients with 
metastatic urothelial carcinoma (UC) have been derived from clinical trial populations of cisplatin-
treated patients.
Objective—To develop a new model based on ‘real world’ patients.
Design, Setting, Participants—Individual patient-level data from 29 centres was collected, 
including metastatic UC and first-line cisplatin- or carboplatin-based chemotherapy administered 
between 01/2006 and 01/2011.
Intervention—First-line, platinum-based, combination chemotherapy.
Outcome measures and statistical analysis—The population was randomly split into a 
development and a validation cohort. Generalized boosted regression modelling was used to screen 
out irrelevant variables and address multivariable analyses. Two nomograms were built to estimate 
OS probability, the first based on baseline factors and platinum agent, the second incorporating 
objective response (OR). The performance of the above nomograms and that of other available 
models was assessed. We plotted decision curves to evaluate the clinical usefulness of the two 
nomograms.
Results and limitations—A total of 1,020 patients were analysed (development: 687; 
validation: 333). In a platinum-stratified Cox model, significant variables for OS were 
performance status (p<0.001); white blood cell count (p=0.013); body mass index (p=0.003); 
ethnicity (p=0.012); lung, liver, or bone metastases (p<.001); and prior perioperative 
chemotherapy (p=0.012). The c-index was 0.660. The distribution of the nomogram scores was 
associated with OR (p<0.001), and incorporating OR into the model further improved the c-index 
in the validation cohort (0.670).
Conclusions—We developed and validated two nomograms for OS to be used before and after 
completion of first-line chemotherapy for metastatic UC.
Patient summary—We proposed two models for estimating OS of patients with metastatic UC 
receiving firstline, platinum-based chemotherapy. These nomograms have been developed on real 
world patients who were treated outside of clinical trials and may be used irrespective of the 
chemotherapeutic platinum agent.
Keywords
Urothelial carcinoma; Overall Survival; Prognosis; Platinum chemotherapy; Nomogram
Introduction
After several decades of therapeutic stagnation in the field of urothelial carcinoma (UC), the 
advent of immunotherapy, that has just revitalized the therapeutic landscape of the salvage 
therapy options, hold promise to also change the paradigm in the first-line metastatic setting.
[1–4] Therefore, there is growing interest in developing a new prognostic model that would 
allow investigators to compare results of experimental and standard therapies and that can be 
easily used in all patients in clinical practice. Many prognostic factors have been proposed 
over the last 15 years, and many of them were derived from clinical trial cohorts or small 
single-centre experiences. These factors included performance status (PS) and the presence 
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of visceral (i.e., lung, liver, or bone [LLB]) metastases.[5,6] Subsequently, these 
characteristics have been augmented with additional factors like albumin, haemoglobin, 
leukocyte count and number of metastatic sites.[7,8] In general, all models have relied on 
clinical trial populations and included cisplatin-treated patients only. However, we know that 
almost half of the patients who require systemic therapy for metastatic UC are not 
considered eligible for cisplatin treatment for many reasons, and carboplatin is used instead, 
despite its documented inferior efficacy.[9,10] Currently, there are no prognostic models for 
carboplatin-treated patients, and some investigators are now questioning the need to separate 
cisplatin- from carboplatin-treated patients in clinical trials.[11]
If available, a unique prognostic model covering both of these therapeutic options would be 
more applicable in ‘real world’ practice as well as for better clinical trial planning. An 
additional benefit would be the possibility of updating the prognostic assessment on the 
basis of the response to chemotherapy observed in individual patients. The little information 
that is currently available is one post-treatment nomogram, which is also based on a 
cisplatin-treated and trial-based patient population.[12]
Patients and Methods
Patient selection
The Retrospective International Study of Invasive/Advanced Cancer of the Urothelium 
(RISC) is a retrospective study including individual patient-level data from patients with 
muscle-invasive or advanced UC or non-UC histology who have received systemic therapy 
in any clinical setting. This contemporary database includes data gathered from January 1st, 
2006 to January 1st, 2011 from hospitals in the United States, Europe, Israel, and Canada.
At the end of October 2015, data were extracted to select patients who fulfilled the following 
characteristics: any tumour primary site, predominant UC histology, de novo metastatic UC 
(including regional lymph-nodes or distant metastatic disease) or relapse after radical 
surgery, and administration of cisplatin- or carboplatin-containing chemotherapy in the first-
line metastatic setting. Data analysis was performed at the Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milano, Italy. The present study was approved by the ethics 
committees at each participating institution.
Statistical analyses
The study objective was to determine prognostic features associated with overall survival 
(OS) in a large contemporary cohort of patients with metastatic UC treated with platinum-
based chemotherapy outside of clinical trials. Accordingly, a nomogram for OS prediction 
was developed, including selected baseline factors and the platinum agent. An additional 
aim was to investigate the possible surrogate or prognostic role of the objective response 
(OR) to first-line chemotherapy to improve nomogram predictions. OR were assessed at 
each site by the local investigators. Descriptive statistics were used to summarize baseline 
characteristics, treatments and outcomes. The Kaplan-Meier method was used for estimation 
of progression-free survival (PFS) and OS, while the reverse Kaplan-Meier method 
described by Schemper and Smith was used for follow-up quantification.[13]
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The analyses were performed using a split-sampling strategy: the overall sample was 
randomly split with stratification by centre into development and validation cohorts. The 
former was used for model building, and the latter was used only for model testing purposes.
For model building, generalized boosted regression modelling (GBM) was used first for 
exploratory purposes, i.e. to screen out irrelevant variables in terms of association with PFS 
and OS.[14] This tree-based regression approach, which is able to incorporate observations 
with partially missing data, also provided guidance for the detection of nonlinear effects and 
interactions among covariates, which was useful for the subsequent phase of analysis. The 
variables with a relative influence lower than 1 were discarded, while the remaining 
variables were entered into multivariable Cox proportional hazards (PH) regression models 
and selected with a p value-based backward procedure. Missing values were substituted with 
the median in case of continuous covariates or considered a separate class of categorical 
covariates. PH assumptions were graphically assessed, and the results of the final models 
were summarized using hazard ratios (HR), together with the corresponding 95% confidence 
intervals (CI) and Wald’s p-values. Finally, a nomogram was built for estimating 1-, 2- and 
5-year OS probability (i.e. RISC1 nomogram). Furthermore, the distribution of the 
nomogram scores was compared between the distinct OR categories using a Kruskal-Wallis 
test. A second nomogram for OS was then derived from a Cox model including the first 
nomogram scores and OR as predictors (i.e. RISC2 nomogram). Performance testing of the 
two nomograms developed here, as well as the most important published models, was 
assessed in terms of discrimination (Harrell’s c-index),[15] calibration (calibration plots and 
slope of “fit2” model by Crowson et al.) [16] and predictive accuracy (Schemper and 
Henderson Dx statistic).[17] Furthermore, we plotted decision curves to assess the benefits 
of nomogram-assisted decisions in a clinical context.[18]
Statistical analyses were carried out with SAS (version 9.2, SAS Institute, Cary, NC) and R 
software (version 3.2.3, R Foundation for Statistical Computing, Vienna, Austria). Statistical 
significance was set at the conventional 5% two-sided threshold.
Results
Patient characteristics and outcomes
The study flow chart is presented in Figure 1. Of 3,024 registered cases, 1,020 patients, from 
29 contributing centres, were suitable for analyses. The main characteristics of the study 
population are shown in Table 1. There were 639 (62.6%) patients who received cisplatin 
and 381 (37.4%) who received carboplatin chemotherapy. Kaplan-Meier curves of PFS and 
OS in the two groups are shown in Supplementary Figure 1A,B. The reasons for carboplatin 
administration were age (N=51), co-morbidities (N=46), impaired renal function (N=187), 
and other not specified (N=97). Globally, 813 patients had information on the response to 
chemotherapy: 85 (10.5%) achieved a complete response (CR) and 285 (35.1%) achieved a 
partial response (PR), with statistically significant differences between cisplatin and 
carboplatin (chi-squared test, p<0.001). The OS curves based on response are shown in 
Supplementary Figure 2A (for carboplatin chemotherapy) and Supplementary Figure 2B (for 
cisplatin chemotherapy).
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After median follow-up of 31.6 months (95%CI: 29.4–35.0) there were 853 progression and 
664 death events. Of the latter, 594 (89.5%) were due to disease progression, 20 (3%) due to 
other causes and the remaining due to unknown reasons or toxicity. The data were split into 
a development sample (N=687, 67.4%) and a validation sample (N=333, 32.6%) targeting a 
2:1 ratio, and PFS and OS curves were overlapping in the two groups (Supplementary Figure 
3A,B).
Prognostic factors for PFS and OS
The variables selected for analysis of OS after GBM are provided in Supplementary Table 1, 
and results of the multivariable Cox analyses are shown in Table 2. Within the Cox models, 
using platinum type as a covariate or a stratification factor did not impact the results in terms 
of variables retained or model performance. Meaningful interactions between platinum type 
and the remaining covariates could also be ruled out. On this basis, we decided to present 
results obtained with stratified Cox models. This choice had the advantage of allowing 
calculation of a prognostic score independent of treatment and subsequently translating this 
score into the expected OS by accounting for the platinum type. The c-index for OS was 
0.671 (95%CI: 0.641–0.701) in the development cohort and 0.660 (95%CI: 0.617–0.704) in 
the validation cohort. The results of the model assessments are shown in Table 3. Overall, 
performance statistics favoured our models (higher c-index and lower Dx, calibration slopes 
generally consistent with a value of one).
Development of a nomogram for OS
The RISC1 nomogram for estimating 1-, 2-, and 5-year OS is shown in Figure 2A, while 12- 
or 24-month calibration plots are shown in Figures 2B and 2C, respectively. Decision curves 
for the OS model are also shown in Figure 2. The plots show that model-based decisions are 
supported in the range of threshold probabilities of about 20–80% at 12 months (2D) and 
50–80% at 24 months (2E).
Prognostic role of the response to first-line chemotherapy
To analyse the interplay between predictions from baseline prognostic factors, response to 
chemotherapy and OS, we used the data from 737 patients (development cohort: N=506; 
validation cohort: N=231) who had information on response and fulfilled a 4-month 
landmark analysis. We found a significantly different distribution of nomogram scores 
according to the response to chemotherapy (Supplementary Figure 4, p<0.001). This finding 
implies that baseline covariates also predicted the response to chemotherapy. However, by 
modelling the response and nomogram scores together with a new Cox model for OS, both 
factors were statistically significant (Supplementary Table 2), and the c-index increased to 
0.705 (95%CI: 0.670–0.739) and 0.670 (95%CI: 0.619–0.721) in the development and 
validation cohort, respectively. These findings suggest that tumour response must be 
considered an additional prognostic factor rather than a perfect surrogate for OS. The 
corresponding RISC2 nomogram is shown in Figure 3A, with calibration plots at 12 and 24 
months (Figures 3B and 3C). Decision curves for the OS model are also shown in Figure 3. 
The plots show that model-based decisions are supported in the range of threshold 
probabilities of about 25–60% at 12 months (3D) and 30–85% at 24 months (3E).
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Discussion
We developed and validated two new nomograms for estimating OS that apply to all patients 
with metastatic UC receiving platinum-based first-line chemotherapy. Also, we tested the 
available prognostic models for OS in a large, contemporary population of patients treated 
outside of clinical trials. The prognostic performance was analysed: in general, an 
improvement in the c-index in excess of 0.015 is deemed clinically relevant.[19] 
Consequently, we observed a meaningful performance improvement of our models 
compared to that of the Memorial Sloan-Kettering Cancer Center,[5] Apolo’s nomogram [6] 
and Galsky’s nomogram, which altogether accounted for PS, site of primary tumour, number 
of metastatic sites, albumin level, leukocyte count, and lymph node metastases.[8]
Remarkably, the most intriguing feature of our model is its applicability regardless of the 
type of platinum administered, a factor that has been further confirmed as having an impact 
on OS. Additionally, thanks to the construction of our models through a series drawn from 
current practice rather than a clinical trial population, many artificial factors typically arising 
in experimental setting (centre and patient selection, modalities of treatment administration 
and patient assessment) are unlikely to affect the results.
Some limitations must be recognized as well. First, in spite of the large sample size of both 
development and validation cohorts, an external validation would have strengthened our 
findings. Second, the retrospective nature of the study does not totally rule out that some 
patients were excluded from the RISC database because of missing records. Yet the number 
of missing data was not negligible for ECOG-PS and ethnicity factors, hence the “not 
available” category was introduced in the nomogram. Practical application of this choice 
might be the possibility to use the nomogram in retrospective case-series where the above 
information is also missing. Third, criteria for choosing carboplatin instead of cisplatin were 
rather heterogeneous, being based on either the clinical judgment or the policy of each 
centre. A way to account for the lack of standardization might be the inclusion of co-
morbidity status (e.g. the Charlson comorbidity index) as a covariate into multivariable 
analysis, but this information could not be retrieved in our study. Similarly, we could not 
analyze other potentially meaningful factors like chemotherapeutic dosing, toxicity and 
tolerability, and need for dose reductions or treatment interruption. These factors might have 
accounted for the significant association of age with PFS in our multivariable model. Fourth, 
the study did not foresee a formal definition of response to chemotherapy. However, it is 
plausible that substantial overlap might exist in expert centres between Response Evaluation 
Criteria for Solid Tumours (RECIST) definitions and routine clinical practice. The lack of 
central response assessment and the possible variations in response assessment across the 
centres might partly explain the overlap between survival curves after PR and SD to first-line 
chemotherapy.
Finally, we were not confident in more finely assessing the impact of prior perioperative 
chemotherapy based on the time lapse to the initiation of first-line therapy owing to the lack 
of available data. Nevertheless, the suitability of cisplatin-based first-line therapy after prior 
perioperative cisplatin has been questioned [20] and analysing all platinum treatments does 
make sense.
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The present model did incorporate the two historical factors that are common in most 
available models, i.e., ECOG-PS and LLB metastases, but two interesting and novel factors 
were shown to be significantly associated with OS: BMI and ethnicity. It is plausible that 
decreased BMI is associated with a shorter OS because it could be a surrogate for weight 
loss or cachexia. Regarding ethnicity, that was self-reported by patients in each case to avoid 
misunderstanding, it is possible that underlying differences in either the disease biology or 
pharmacogenomics may be responsible for the different survival, and further investigation is 
warranted. No differences in access to second-line therapy based on ethnicity could be found 
(data not shown), and socioeconomic information was not recorded in the database.
Despite the decision thresholds of the two nomograms suggested a net benefit over a fairly 
limited range at long term, these nomograms may be offered as possible aids to clinicians in 
the context of limited validated options for risk estimation. The RISC1 nomogram might be 
best applied to stratify the results in randomized clinical trials in which a standard 
chemotherapy arm is used. Examining the RISC2 nomogram, we observed an increase in the 
prognostic ability leading to a c-index of approximately 0.70 after the inclusion of tumour 
response as a predictor, together with baseline factors. Such a result was obtained in spite of 
a statistically significant association between the two nomogram components. This 
association is an original finding in the field of advanced UC, although caution is needed in 
interpreting the results owing to the acknowledged limitations.
Galsky et al. has already presented a post-treatment nomogram based on 317 cisplatin-
treated patients, and its prognostic ability was equally good (c-index of 0.68).[12] Our 
proposal, however, has the advantage of expanding the field of applicability to all patients 
who had received a platinum-based combination chemotherapy. The applicability of the 
RISC2 may be twofold: in real world practice, where follow-up planning and patient 
counseling at the end of first-line chemotherapy may be better addressed; in the context of 
clinical trials, where the nomogram may provide the benchmark of expected OS with 
standard treatment and interest lies in investigating maintenance therapy. To make these new 
prognostication tools more user friendly, a free app called “RISCalculator” is being 
developed for smartphones and tablets and will be available in the app stores. Formulas for 
calculating estimated survival for individual patients are available to the reader upon request.
Conclusions
We developed and tested nomograms for estimating the OS of patients with metastatic UC 
receiving first-line platinum-based chemotherapy. The nomograms we developed were based 
on contemporary real world patients who were treated outside of clinical trials, included 
newly identified prognostic factors, and allowed for the response to chemotherapy. External 
validation of the present models and nomograms is warranted. Owing to the broad 
applicability of the baseline and post-treatment nomogram, and the comparatively improved 
performance of both, their use may be recommended.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Study flow chart, with counts and reasons for patient selection.
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Figure 2. 
A) RISC1 nomogram to predict individual patient-level 1-, 2-, and 5-year overall survival 
based on baseline factors before starting first-line chemotherapy. B) Calibration plots for the 
validation sample of the RISC1 nomogram, estimated at 12 months, and C) 24 months. The 
average predicted probability (nomogram-predicted overall survival; x-axis) was plotted 
against Kaplan-Meier estimate (observed overall survival; y-axis). 95% confidence intervals 
of the Kaplan-Meier estimates are indicated with vertical lines. Red line indicates the 
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reference line, indicating where an ideal nomogram would lie. D) Decision curves for 
overall survival at 12 and E) 24 months applied to the RISC1 nomogram.
Legend: solid thin line: net benefit of a strategy of treating all patients; solid bold line: net 
benefit of treating no patients; dotted line: net benefit of a strategy of treating patients 
according to the nomogram predictions.
Abbreviations: BMI: body-mass index; ECOG-PS: Eastern Cooperative Oncology Group 
Performance Status; NA: not available; RISC: Retrospective International Study of Invasive/
Advanced Cancer of the Urothelium; WBC: white blood cell count.
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Figure 3. 
A) RISC2 nomogram to predict individual patient-level 1-, 2-, and 5-year overall survival 
based on the response to first-line chemotherapy added to the total score from RISC1. B) 
Calibration plots for the validation sample of the RISC2 nomogram, estimated at 12 months, 
and C) 24 months. D) Decision curves for overall survival at 12- and 24- (E) months applied 
to the RISC2 nomogram.
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Legend: solid thin line: net benefit of a strategy of treating all patients; solid bold line: net 
benefit of treating no patients; dotted line: net benefit of a strategy of treating patients 
according to the nomogram predictions.
Abbreviations: CR: complete response; CT: chemotherapy; PD: progressive disease; PR: 
partial response; NA: not available; RISC1: nomogram with baseline factors from the 
Retrospective International Study of Invasive/Advanced Cancer of the Urothelium database; 
SD: stable disease.
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Table 1
Patient, disease, and treatment characteristics
No. %
Total number of patients 1,020 -
Age, years: median (IQR) 67 (59–73)
Gender
 Male 802 78.6
 Female 211 20.7
 Missing 7 0.7
Ethnicity
 Not Hispanic/latino, White 831 81.5
 Not Hispanic/latino, Black 29 2.8
 Hispanic or latino 81 7.9
 Other or mixed 22 2.2
 Missing 57 5.6
Smoking history
 Current smoker 220 21.5
 Former smoker 359 35.2
 Never smoker 226 22.2
 Missing 215 21.1
Primary tumour location
 Bladder 828 81.2
 Renal pelvis or ureter 165 16.2
 Urethra 6 0.6
 Missing 21 2.0
Histology
 Pure UC 923 90.5
 UC with divergent histologies 79 7.7
 Missing 18 1.8
BMI, Kg/m2: median (IQR) 26.3 (23.6–29.1)
ECOG-Performance Status
 0 303 29.7
 1 392 38.4
 2 110 10.8
 >2 20 2.0
 Missing 195 19.1
Baseline Haemoglobin, gr/dL: median (IQR) 12.2 (10.9–13.5)
Baseline WBC, ×103/μL: median (IQR) 8.0 (6.3–10.3)
Prior peri-operative systemic therapy 171 16.8
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No. %
Time from end peri-operative chemotherapy to start first-line, months: median (IQR) 11.0 (4.8–24.5)
 ≤12 months 71 41.5
 >12 months 61 35.7
 Undetermined 39 22.8
Number of metastatic sites
 1 415 40.7
 2 306 30.0
 ≥3 254 24.9
 Missing 45 4.4
Site of metastases
 Pelvic lymph-nodes 391 38.3
 Retroperitoneal lymph-nodes 305 29.9
 Other lymph-nodes 183 17.9
 Lung 258 25.3
 Bone 256 25.1
 Liver 189 18.5
 Pelvic soft tissue 127 12.5
 Peritoneum 30 2.9
 Brain 16 1.6
 Other 152 14.9
Type of first-line chemotherapy
Cisplatin-based combination 639 62.6
 Gemcitabine and cisplatin 429 67.2
 MVAC or DD-MVAC 167 26.1
 Taxane, cisplatin, and gemcitabine 9 1.4
 Other 34 5.3
Carboplatin-based combination 381 37.4
 Gemcitabine and carboplatin 307 80.6
 Taxane and carboplatin 39 10.2
 Taxane, carboplatin, and gemcitabine 15 3.9
 Other 20 5.3
Response to first-line chemotherapy Total: 813
 CR 85 10.5
 PR 285 35.1
 SD 215 26.4
 PD 228 28.0
Abbreviations: CR: complete response; ECOG: Eastern Cooperative Oncology Group; IQR: interquartile range; (DD)-MVAC: (dose-dense)-
methotrexate, vinblastine, doxorubicin, cisplatin; PD: disease progression; PR: partial response; SD: stable disease; UC: urothelial carcinoma; 
WBC: white blood cell count.
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Table 3
Assessment on the RISC population of the performance of the available platinum-stratified Cox models for 
OS, in terms of discrimination (Harrell c-index), calibration (calibration slope) and accuracy (Schemper and 
Henderson Dx).
Model Development cohort Validation cohort
All patients Cisplatin only All patients Cisplatin only
Bajorin, 1999* [6]
• c-index (95% CI)‡
• calibration slope (95% CI)
• Dx
0.643 (0.613–0.672) 0.622 (0.584–0.660) 0.623 (0.579–0.666)
0.845 (0.683–1.045)
0.541
0.619 (0.563–0.675)
0.762 (0.542–1.071)
0.566
Apolo, 2013* [7]
• c-index (95%CI)‡
• calibration slope (95% CI)
• Dx
0.659 (0.629–0.689) 0.642 (0.603–0.681) 0.636 (0.592–0.679)
0.854 (0.695–1.049)
0.540
0.641 (0.583–0.698)
0.798 (0.575–1.108)
0.564
Galsky, 2013* [8]
• c-index (95% CI)‡
• calibration slope (95% CI)
• Dx
0.666 (0.635–0.696) 0.657 (0.617–0.696) 0.644 (0.600–0.688)
0.841 (0.674–1.049)
0.542
0.645 (0.587–0.702)
0.778 (0.553–1.094)
0.564
Present
• c-index (95%CI)‡
• calibration slope (95% CI)
• Dx
0.671 (0.641–0.701) 0.660 (0.617–0.704)
0.881 (0.715–1.087)
0.534
Abbreviations: CI: confidence interval; OS: overall survival; RISC: Retrospective International Study of Invasive/Advanced Cancer of the 
Urothelium.
*
Type of chemotherapy (cisplatin vs carboplatin) being included into the original model as a covariate.
‡
estimated at 36 months
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